New data from Eli Lilly reveal that 63.5% of ulcerative colitis patients treated with Omvoh maintained disease clearance after four years of continuous treatment. Disease clearance means simultaneous symptom relief, and endoscopic and histologic remission, a high clinical standard linked to fewer hospitalizations and surgeries. This is the first IL-23p19 inhibitor to demonstrate such long-term durable remission, potentially changing the disease's long-term course. Eli Lilly is also exploring combination therapies and pediatric trials to further improve outcomes.
Eli Lilly reported a 56% year-over-year revenue increase to $19.8 billion in Q1 fiscal 2026, driven by its Zepbound and Mounjaro products, which will soon be covered by Medicare. The company posted non-GAAP earnings per share of $8.55, a 156% jump fr...
A bipartisan US congressional committee is investigating whether Merck, AbbVie, and three other major pharmaceutical companies conducted clinical trials in China that may have supported Chinese military capabilities. The inquiry focuses on due dilige...
Innovent Biologics and Eli Lilly have signed an agreement for Innovent to handle importation, marketing, distribution, and promotion of Lilly's breast cancer drug Verzenios (abemaciclib) in mainland China. Lilly will continue manufacturing and produc...
The FDA has selected seven companies, including Eli Lilly and Regeneron, for its new PreCheck pilot program aimed at accelerating regulatory review of new pharmaceutical manufacturing facilities in the U.S. This program allows the FDA to review facil...
